TY - JOUR
T1 - Mouse models of prostate cancer
T2 - Picking the best model for the question
AU - Grabowska, Magdalena M.
AU - Degraff, David
AU - Yu, Xiuping
AU - Jin, Ren Jie
AU - Chen, Zhenbang
AU - Borowsky, Alexander D.
AU - Matusik, Robert J.
N1 - Funding Information:
MMG was supported by the VUMC Integrated Biological Systems Training in Oncology training grant (2 T32 CA119925-06). DJD was supported by an NIH Pathway to Independence Award (1 K99 CA172122), the VUMC Multidisciplinary Training Grant in Molecular Endocrinology (5 T32 DK007563-21), the VUMC Integrated Biological Systems Training in Oncology training grant (1 T32 CA119925), and the American Cancer Society Great Lakes Division-Michigan Cancer Research Fund Postdoctoral Fellowship. XY was supported by Department of Defense (DOD) PC111074. RJJ was supported by the DOD Prostate Cancer Research Program (W81XWH-10-1-0236). ZC was supported by the National Institute on Minority Health and Health Disparities grants MD 5 R01 004038, G12 MD 007586, and 5 U54 CA 163069. AB was supported by NCI (U01 CA141582) and the UC Davis Extension Genomic Pathology online course in Pathobiology of the Mouse (http:// extension.ucdavis.edu/unit/health_sciences/pdf/114150_Genomic.pdf). RJM was supported by the NCI (R01-CA076142-14) and NIDDK (R01-DK055748-13).
PY - 2014/9
Y1 - 2014/9
N2 - When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for "prostate cancer mouse model" yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?
AB - When the National Institutes of Health Mouse Models of Human Cancer Consortium initiated the Prostate Steering Committee 15 years ago, there were no genetically engineered mouse (GEM) models of prostate cancer (PCa). Today, a PubMed search for "prostate cancer mouse model" yields 3,200 publications and this list continues to grow. The first generation of GEM utilized the newly discovered and characterized probasin promoter driving viral oncogenes such as Simian virus 40 large T antigen to yield the LADY and TRAMP models. As the PCa research field has matured, the second generation of models has incorporated the single and multiple molecular changes observed in human disease, such as loss of PTEN and overexpression of Myc. Application of these models has revealed that mice are particularly resistant to developing invasive PCa, and once they achieve invasive disease, the PCa rarely resembles human disease. Nevertheless, these models and their application have provided vital information on human PCa progression. The aim of this review is to provide a brief primer on mouse and human prostate histology and pathology, provide descriptions of mouse models, as well as attempt to answer the age old question: Which GEM model of PCa is the best for my research question?
UR - http://www.scopus.com/inward/record.url?scp=84905088552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84905088552&partnerID=8YFLogxK
U2 - 10.1007/s10555-013-9487-8
DO - 10.1007/s10555-013-9487-8
M3 - Review article
C2 - 24452759
AN - SCOPUS:84905088552
SN - 0167-7659
VL - 33
SP - 377
EP - 397
JO - Cancer and Metastasis Reviews
JF - Cancer and Metastasis Reviews
IS - 2-3
ER -